Richard Eisenstadt, Tranzyme Pharma's chief financial officer, is resigning effective Jan. 4 to pursue a new career opportunity, the Durham company announced Wednesday.
"On behalf of the entire team at Tranzyme Pharma, I would like to thank Rich for his many years of hard work and dedication at the company during his tenure as CFO," CEO Vipin K. Garg said in a statement. "Since joining Tranzyme in 2003, Rich has been a valuable member of our executive team. We wish him the best in his future endeavor."
Tranzyme's controller, Rhonda L. Stanley, will take over Eisenstadt's CFO duties after he departs.